In Brief: Butenafine
This article was originally published in The Tan Sheet
Executive Summary
Butenafine: Foster City, Calif.-based Penederm's topical antifungal receives approval for OTC treatment of athlete's foot in Canada, the company announces. The product will be marketed by Schering-Plough, which intends to market the fungicide under one of its brand names: Lotrimin, Tinactin or Dr. Scholl's. Penederm says the launch will take place later this year. Penederm launched the ingredient earlier this year in the U.S. as Mentax, a Rx treatment for athlete's foot, ringworm and jock itch. Schering holds U.S. OTC rights for the ingredient but a switch will not occur for several years because of the licensing agreement...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning